Mark Elliott Boulding

Companies

• PTC TherapeuticsGeneral counsel Jun 19, 2013 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• PTC Therapeutics PTCT105,272 shares²$6.4M at $60.99Aug 17, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Aug 17, 2026Sold 969 shares at $72.90 of PTC Therapeutics²
• Aug 17, 2026Sold 1,844 shares at $72.39 of PTC Therapeutics²
• Aug 17, 2026Exercised options 2,813 shares at $25.69 of PTC Therapeutics²
• Jul 6, 2026Sold 745 shares at $86.38 of PTC Therapeutics³
• Jul 6, 2026Sold 645 shares at $85.84 of PTC Therapeutics³
• Jul 6, 2026Sold 1,036 shares at $84.41 of PTC Therapeutics³
• Jul 6, 2026Sold 387 shares at $83.10 of PTC Therapeutics³
• Jul 6, 2026Exercised options 2,813 shares at $46.54 of PTC Therapeutics³
• Jul 6, 2026Sold 601 shares at $86.38 of PTC Therapeutics³
• Jul 6, 2026Sold 519 shares at $85.84 of PTC Therapeutics³
• Jul 6, 2026Sold 833 shares at $84.41 of PTC Therapeutics³
• Jul 6, 2026Sold 313 shares at $83.10 of PTC Therapeutics³
• Jul 6, 2026Exercised options 2,266 shares at $39.42 of PTC Therapeutics³
• Jun 17, 2026Sold 309 shares at $79.25 of PTC Therapeutics⁴
• Jun 17, 2026Sold 1,703 shares at $78.50 of PTC Therapeutics⁴
• Jun 17, 2026Exercised options 2,012 shares at $46.54 of PTC Therapeutics⁴
• Jun 17, 2026Sold 1,850 shares at $79.24 of PTC Therapeutics⁴
• Jun 17, 2026Sold 6,600 shares at $78.50 of PTC Therapeutics⁴
• Jun 17, 2026Exercised options 8,510 shares at $46.54 of PTC Therapeutics⁴
• May 15, 2026Sold 456 shares at $72.67 of PTC Therapeutics⁵
• May 15, 2026Sold 2,356 shares at $72.08 of PTC Therapeutics⁵
• May 15, 2026Exercised options 2,812 shares at $25.69 of PTC Therapeutics⁵
• May 8, 2026Sold 600 shares at $79.28 of PTC Therapeutics⁶
• May 8, 2026Sold 200 shares at $78.00 of PTC Therapeutics⁶
• May 8, 2026Exercised options 800 shares at $46.54 of PTC Therapeutics⁶